Results 71 to 80 of about 22,482 (226)

Neovascular glaucoma at a tertiary Centre in Finland, 2008–2024: A retrospective cohort study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes. Methods Patients with NVG were identified through electronic medical record review.
Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju   +3 more
wiley   +1 more source

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BMC Ophthalmology, 2018
Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann   +9 more
doaj   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial

Ophthalmology (Rochester, Minn.), 2016
Purpose Provide 2-year efficacy, safety and treatment results comparing three anti-vascular endothelial growth factor (anti-VEGF) agents for center-involved diabetic macular edema (DME) utilizing a standardized follow-up and retreatment regimen.
John A. Wells, Adam R. Glassman, Allison R. Ayala, Lee M. Jampol, Neil M. Bressler, S. Bressler, Alexander J. Brucker, Frederick L. Ferris, G. Robert Hampton, Chirag Jhaveri, M. Melia, Roy W. Beck   +11 more
semanticscholar   +1 more source

Radiomics Analysis for Predicting Medication‐Related Osteonecrosis of the Jaw Using Computed Tomography

Oral Diseases, EarlyView.
ABSTRACT Objectives To determine whether pretreatment radiomics can predict medication‐related osteonecrosis of the jaw (MRONJ). Methods Patients with mandibular MRONJ at Hiroshima University Hospital (2009–2024) who underwent MDCT before initiating bone resorption inhibitors were retrospectively identified. Records from 2009 to 2020 were also reviewed
Masaru Konishi
wiley   +1 more source

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion

Clinical Ophthalmology, 2017
Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi Ophthalmology Department, Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan Purpose: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in
Tagami M, Sai R, Fukuda M, Azumi A
doaj  

Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis

Frontiers in Pharmacology
BackgroundThis study aimed to evaluate the aflibercept biosimilars compared to the reference product aflibercept (Eylea®) in terms of efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).MethodsWe ...
Yating Zhou, Zongyue Zhan, Zixun Wang, Chen Liu   +3 more
doaj   +1 more source

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

International Journal of Cancer, Volume 159, Issue 7, Page 1817-1828, 1 October 2026.
Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning   +17 more
wiley   +1 more source

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy

JAMA ophthalmology
This secondary analysis of the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) randomized ...
Won Ki Lee, Tien Y. Wong, Shih-Jen Chen, Xiaodong Sun, Chui Ming Gemmy Cheung, Rufino Silva, F. Ricci, Xin Zhang, Tobias Machewitz, Andrea Schulze, U. Schmidt-Ott, Min Zhao, Z. Hasanbasic, Sergio Leal, Tomohira Iida   +14 more
semanticscholar   +1 more source

The impact of systemic long‐term medications for the development of age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 6, Page 674-681, September 2026.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä, Reijo Sund, Toni Rikkonen, Kai Kaarniranta   +3 more
wiley   +1 more source